All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AZD7442
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD7442
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: $486.0 million Upfront Cash: Undisclosed
Deal Type: Agreement October 09, 2020
Details:
AstraZeneca plans to supply up to 100,000 doses of AZD7442 starting towards the end of 2020 and the US Government can acquire up to an additional one million doses in 2021 under a separate agreement.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AZD7442
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD7442
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
Details:
Notable abstracts include data from the first randomized controlled Phase 3 study of a PCSK9 inhibitor, Repatha, in pediatric patients with heterozygous familial hypercholesterolemia (HeFH), which will be presented as a late-breaking abstract in an oral presentation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NVX-COV2373,Matrix-M
Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: U.S Government
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 27, 2020
Details:
FUJIFILM Diosynth will support COVID-19 vaccine candidate manufacturing, as part of Operation Warp Speed, a U.S. government program that aims to begin delivering millions of doses of a safe, effective vaccine for COVID-19 to the U.S. population.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CoVLP vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Medicago
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 07, 2020
Details:
GSK and Medicago have formed a collaboration to develop and evaluate a COVID-19 candidate vaccine combining Medicago’s recombinant Coronavirus Virus-Like Particles (CoVLP) with GSK’s pandemic adjuvant system.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ChAdOx1-HBV
Therapeutic Area: Infections and Infectious Diseases Product Name: VTP-300
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2020
Details:
HBV001 is an open-label, non-randomised, dose escalation study, comparing the safety, tolerability and immunogenicity of two different doses of the VTP-300 prime, ChAdOx1-HBV, across three sites in the UK.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MRx-4DP0004
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2020
Details:
4d Pharma has received expedited acceptance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to commence a Phase II study of MRx-4DP0004 in patients with COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Set-point vaccines
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Vickers Venture Partners
Deal Size: $11.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 09, 2020
Details:
The financing will support a first-in-man Phase I clinical trial of its Flavivirus (Dengue) vaccine in Switzerland, as well as Phase Ib clinical trials in the endemic regions of Singapore and Brazil.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
